Drug Trial Radar · NCT04097769
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jun 12, 2019
Primary completion
Mar 18, 2021
Study completion Sep 29, 2022
Sponsor
- Lead sponsor
- Waterstone Hanxbio Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multicenter, open-label, multiple-dose Phase I study to investigate the safety, tolerability, and initial efficacy of HX009 in subjects with advanced malignant tumors. The study will consist of a dose-escalation and dose-finding component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and to evaluate the preliminary antitumor activity of HX009.
Conditions
- Advanced Solid Tumor
Interventions
HX009Drug
During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events (AEs)Time frame: All AEs up to 90 days after the last dose of study drug
- Number of Participants With Dose-Limiting Toxicities (DLT) of HX009Time frame: At the end of Cycle2(each cycle is 14 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St George Private Hospital
Kogarah, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.